Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1,707 enrolled

Overview

CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.

Study Type

OBSERVATIONAL

Enrollment

1,707

Conditions

Covid19

Interventions

Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19OTHER

Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau, * Positive COVID-19 polymerase chain reaction test * Length of stay more than 24 hours Exclusion Criteria: * No objective diagnose for COVID-19 * Outpatient * Lenght of stay less than 24hours

Locations (1)

Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, Spain

Outcomes

Primary Outcomes

Mortality

Time frame: From hospital admission to day 28

Transfer to the Intensive Care Unit (ICU)

Time frame: From hospital admission to day 28

Secondary Outcomes

Thromboembolic complications

Venous thromboembolism, ischemic stroke, myocardial infarction or periferal arterial thrombosis during hospitalization for Covid19

Time frame: From hospital admission to day 28

Major bleeding complications

Any bleeding complication grade 3 or 5 according BARC classification

Time frame: From hospital admission to day 28

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.